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Abstract. 
 
Bax, a member of the Bcl-2 protein family, 
accelerates apoptosis by an unknown mechanism. Bax 
has been recently reported to be an integral membrane 
protein associated with organelles or bound to or-
ganelles by Bcl-2 or a soluble protein found in the cyto-
sol. To explore Bcl-2 family member localization in liv-
ing cells, the green fluorescent protein (GFP) was fused 
to the NH
 
2
 
 termini of Bax, Bcl-2, and Bcl-X
 
L
 
. Confocal 
microscopy performed on living Cos-7 kidney epithelial 
cells and L929 fibroblasts revealed that GFP–Bcl-2 and 
GFP–Bcl-X
 
L
 
 had a punctate distribution and colocal-
ized with a mitochondrial marker, whereas GFP–Bax 
was found diffusely throughout the cytosol. Photo-
bleaching analysis confirmed that GFP–Bax is a soluble 
protein, in contrast to organelle-bound GFP–Bcl-2. The 
diffuse localization of GFP–Bax did not change with 
coexpression of high levels of Bcl-2 or Bcl-X
 
L
 
. How-
ever, upon induction of apoptosis, GFP–Bax moved in-
tracellularly to a punctate distribution that partially 
colocalized with mitochondria. Once initiated, this Bax 
movement was complete within 30 min, before cellular 
shrinkage or nuclear condensation. Removal of a 
COOH-terminal hydrophobic domain from GFP–Bax 
inhibited redistribution during apoptosis and inhibited 
the death-promoting activity of both Bax and GFP–
Bax. These results demonstrate that in cells undergoing 
apoptosis, an early, dramatic change occurs in the intra-
cellular localization of Bax, and this redistribution of 
soluble Bax to organelles appears important for Bax to 
promote cell death.
 
P
 
rogrammed 
 
cell death is vital for both normal de-
velopment and maintenance of many tissues in mul-
ticellular organisms. A form of programmed cell
death, apoptosis, proceeds with morphological and bio-
chemical characteristics that include blebbing of the cell
membrane, a decrease in cell volume, nuclear condensa-
tion, and the intranucleosomal cleavage of DNA (37).
The family of Bcl-2–related proteins plays key roles in
the regulation of apoptosis. Individual family members can
function to either block or promote programmed cell
death (38). Three extensively characterized mammalian
family members are the antiapoptotic genes 
 
bcl-2
 
 and 
 
bcl-
X
 
L
 
, and the proapoptotic gene 
 
bax.
 
 In vivo studies suggest
that a single protein product predominates for each gene:
Bcl-2
 
a
 
, a 26-kD protein (36); Bcl-X
 
L
 
, a 27-kD protein (9);
and Bax
 
a
 
, a 21-kD protein (27). (Bcl-2
 
a
 
 and Bax
 
a
 
 hereaf-
ter will be referred to as Bcl-2 and Bax.) Bcl-2, Bcl-X
 
L
 
, and
Bax each contain a stretch of hydrophobic amino acids,
 
z
 
20 residues in length, at their COOH termini. There is
little amino acid sequence conservation within these tails,
but based on hydropathy plot analysis they are presumed
to function in anchoring these proteins into organelle mem-
branes (2, 25). Bcl-2 has been localized to the nuclear
membrane, endoplasmic reticulum, and the outer mito-
chondrial membranes (3, 12, 19, 24). Removal of the
COOH-terminal tail from Bcl-2 changes the subcellular
localization to the cytosol, but it remains unclear what ef-
fect the removal of the tail has on the ability of Bcl-2 to in-
hibit apoptosis (1, 2, 13, 35). Bcl-X
 
L
 
 also has been localized
to the outer membrane of mitochondria (9). Although the
localization of Bax has been less extensively investigated,
Bax has been suggested to be targeted to organelle mem-
branes (11), and in particular to mitochondria (39) by a
COOH-terminal hydrophobic region. However, it was re-
cently reported that in BHK cells, low level expression of
Bax had a punctate, organelle localization whereas over-
expressed Bax displayed a diffuse cytosolic distribution
when visualized by immunocytochemistry (32). In that
study, coexpression of high levels of Bcl-2 led to a punc-
tate distribution of Bax, suggesting that Bax association
with organelle membranes required Bcl-2. In another re-
cent study, the endogenous Bax in murine thymocytes,
splenocytes, and HL-60 human leukemia cells was found
by subcellular fractionation to be predominantly soluble,
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localized separately from membrane-bound Bcl-2 (14, 15).
During thymocyte apoptosis, a significant fraction of the
Bax was found to redistribute from the cytosol to mem-
branes. This latter finding raises the possibility of the regu-
lation of Bax subcellular localization during apoptosis (14).
Previous investigations of Bax localization have relied
upon cell fixation or fractionation. In this study, we exam-
ine Bax localization in living cells. The genes encoding hu-
man Bcl-2, Bcl-X
 
L
 
, and Bax were fused to that of the green
fluorescent protein (GFP),
 
1
 
 and herein we report the lo-
calization by confocal microscopy of these fusion proteins
in both healthy cells and cells undergoing apoptosis. The
time course of changes in GFP–Bax localization relative to
other cellular events occurring during apoptosis was char-
acterized. Furthermore, the influence of Bcl-2 and Bcl-X
 
L
 
overexpression on Bax localization was examined. We
have deleted the COOH-terminal hydrophobic tails from
Bax, Bcl-2, and Bcl-X
 
L
 
 to investigate the importance of
these regions in the subcellular localization, and the ability
of these proteins to influence cell death.
 
Materials and Methods
 
Except as noted, reagents were purchased from Sigma Chemical Co. (St.
Louis, MO).
 
Generation of Expression Constructs
 
Full-length and COOH-terminal truncated forms (
 
D
 
CT) of human Bcl-2,
Bcl-X
 
L
 
, and Bax were synthesized by PCR amplification and cloned into
the pcDNA-3 mammalian expression vector (Invitrogen, Carlsbad, CA).
A similiar strategy was used for GFP-fusion constructs, using the C3-
EGFP plasmid (Clontech Laboratories, Inc., Palo Alto, CA). The cDNAs
for human 
 
bcl-2
 
, human 
 
bcl-X
 
L
 
, and human 
 
bax
 
 were gifts of C.M. Croee
(Jefferson Cancer Center, Philadelphia, PA), C.B. Thompson (HHMI and
University of Chicago, Chicago, IL), and S.J. Korsmeyer (HHMI and
Washington University, St. Louis, MO), respectively. The 
 
bcl-2
 
 
 
D
 
CT, 
 
bcl-
X
 
L
 
 
 
D
 
CT, and 
 
bax
 
 
 
D
 
CT forms constructed encode for proteins which have
a deletion of 23, 25, and 21 amino acids at their COOH-terminal ends, re-
spectively. For full-length constructs of each gene, oligonucleotides plac-
ing a restriction enzyme site immediately adjacent to the start codon (for-
ward primers) or stop codon (reverse primers) were synthesized (GIBCO
BRL, Gaithersburg, MD). For the truncated (
 
D
 
CT) forms, a stop codon
was introduced by the reverse primers. PCR was performed using Pfu
polymerase (Stratagene, La Jolla, CA) to minimize errors. PCR fragments
were purified, digested with restriction enzymes, and ligated into the ex-
pression vectors. The 
 
bcl-X
 
L
 
, 
 
bcl-X
 
L
 
D
 
CT
 
, 
 
bcl-2
 
, and 
 
bcl-2 
 
D
 
CT
 
 genes were
subcloned between the XhoI and XbaI sites in the polycloning regions of
both pcDNA3 and C3-EGFP. The 
 
bax
 
 and 
 
bax 
 
D
 
CT
 
 genes were sub-
cloned between the HindIII and EcoRI sites in the polycloning regions of
both pcDNA3 and C3-EGFP. All constructs were sequenced using the Se-
quenase 2 kit (United States Biochemical Corp., Cleveland, OH).
 
Cell Culture and Transient Transfection
 
L929 murine fibrosarcoma and Cos-7 green monkey renal epithelia cell
lines (American Type Culture Collection, Rockville, MD) were grown in
Minimum essential medium, Eagle’s in Earle’s balanced salt solution and
DME, respectively, each supplemented with 2 mM glutamine, 1
 
3
 
 nones-
sential amino acids, 2.5 mM sodium pyruvate, 100 U/ml penicillin, 100 
 
m
 
g/
ml streptomycin (all from Biofluids Inc., Rockville, MD), 50 
 
m
 
g/ml gen-
tamicin (GIBCO BRL), and 10% heat-treated FCS. Cells were cultured at
37
 
8
 
C in 5% CO
 
2
 
 and then split twice weekly using 0.05% trypsin/0.02%
versene (Biofluids Inc.). In preparation for transfection, cells were plated
at a density of 2 
 
3
 
 10
 
5
 
 cells per well in six-well tissue-culture plates (Bec-
ton Dickinson Labware, Bedford, MA). Either one (Cos-7) or two (L929)
 
days later, cells were transiently transfected using the cationic lipid Lipo-
fectAmine (GIBCO BRL) as described by the manufacturer, using 2 
 
m
 
g
of plasmid DNA and either 8 (L929) or 10 
 
m
 
l (Cos-7) of LipofectAmine
per well. After 5 h in serum-free medium, an equal volume of medium
containing 2
 
3
 
 normal FCS was added. 1 d after transfection, the cells
were washed once and placed in normal growth media. Transfected cells
were then cultured for an additional 24 h, and visualized by microscopy.
For cotransfection experiments (see Fig. 7), the above procedure was fol-
lowed, except that a total of 4 
 
m
 
g of plasmid DNA was used per well: 1 of
C3–EGFP–Bax and 3 of either pcDNA3–Bcl-2 or pcDNA3–Bcl-X
 
L
 
.
 
Generation of Anti–human Bcl-2 Monoclonal Antibody
 
A peptide corresponding to amino acids 41–54 of human Bcl-2 (GAAPA-
PGIFSSQPGC; Peptide Technologies Corp., Gaithersburg, MD) was con-
jugated to maleimide-activated keyhole limpet hemocyanin (KLH) (Pierce
Chemical Co., Rockford, IL) through the cysteine residue according to the
protocol provided by the manufacturer. Mice were immunized with the
peptide–KLH conjugate and splenocytes from immunoreactive mice were
fused by PEG 4,000 to murine NS-1 myeloma cells and selected with his-
tone acetyltransferase (HAT) medium as previously described (15). The
anti–human Bcl-2 antibody was designated 
 
a
 
hBcl-2 8C8.
 
Cell Lysis and Western Blotting
 
Transfected cells from two wells of a six-well plate were washed once with
PBS and then lysed in cold solubilization buffer (PBS, 25 
 
m
 
g/ml phenyl-
methylsulphonyl fluoride, 1 
 
m
 
g/ml leupeptin, and 1 
 
m
 
g/ml aprotinin) con-
taining 1% Triton X-100. For Western blotting, 20 
 
m
 
l of each sample were
separated by electrophoresis using 12% SDS-PAGE gels. Gels were elec-
trotransferred onto Immobilon-P (Millipore Corp., Waters Chromatogra-
phy, Milford, MA) membranes. The blots were blocked in PBS/0.05%
Tween 20 containing 5% fetal bovine serum and incubated with the ap-
propriate antibody: anti–human Bcl-2 8C8, anti-universal Bcl-X
 
L
 
 2H12
(15), or anti–human Bax 2D2 monoclonal antibodies (15). Primary anti-
body binding was detected by blotting with sheep anti–mouse F(ab’)
linked to horseradish peroxidase (Amersham Corp., Arlington Heights,
IL), followed by band visualization using enhanced chemiluminescence as
described by the manufacturer (Amersham Corp.).
 
Confocal Microscopy
 
Cells used for confocal microscopy were transfected as described above
on 1.5 thickness glass coverslips pretreated with 5 
 
m
 
g/ml poly-
 
l
 
-lysine. Af-
ter 24–48 h, cells were prepared for microscopy by incubation with 20 ng/
ml of a mitochondrion-specific dye (Mitotracker Red CMXRos; Molecu-
lar Probes Inc., Eugene, OR) and/or 100 ng/ml bis-benzamide for 30 min,
as indicated in individual experiments. After pretreatment, cells were
transferred to a sealed mounting chamber containing fresh medium; in in-
dicated experiments, this medium was supplemented with 1–3 
 
m
 
M stauro-
sporine (STS). Images were collected on a microscope (model LSM 410
with a 40
 
3
 
 1.2 NA Apochromat objective; Carl Zeiss, Thornwood, NY).
The 488- and 568-nm lines of a krypton/argon laser were used for fluores-
cence excitation of GFP and Mitotracker Red CMXRos, respectively, and
the 364-nm line of an argon laser was used for excitation of bis-benzamide
dye. The temperature of the specimen was maintained between 35
 
8
 
 and
37
 
8
 
C with an air stream incubator.
To investigate the mobility of the GFP-fusion proteins, the fluores-
cence within a region of a cell was photobleached by scanning the region
with the 488-nm laser line at full power (no attenuation) and then the en-
tire cell was scanned at 10-s intervals with low laser power (10% power,
0.3% attenuation) to monitor the recovery of fluorescence. The fraction
of the fluorescent protein that was mobile was calculated as described (4)
by comparing the fluorescence intensities in two regions of the cell, one
inside the photobleach zone and the other elsewhere, before and 100 s af-
ter the photobleach (mobile fraction 
 
5
 
 ratio after 100-s recovery/ratio be-
fore photobleach). The time course of fluorescence recovery was deter-
mined by photobleaching a 16-
 
m
 
m strip within a flattened area of the cell
and then monitoring the recovery of fluorescence within the strip (200 im-
ages at 0.46-s intervals).
 
Cell Viability Assay
 
To assess the effects of the full-length and 
 
D
 
CT forms of Bcl-2, Bcl-X
 
L
 
,
and Bax, on cell viability, a cotransfection assay was performed in L929 or
Cos-7 cells. Wells plated as described above were cotransfected with one
 
1. 
 
Abbreviations used in this paper
 
: 
 
D
 
CT, COOH-terminal truncation;
DIC, differential interference contrast; GFP, green fluorescent protein;
STS, staurosporine. 
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vector construct containing a given gene in pcDNA3, and the second vec-
tor, EGFP (Clontech Laboratories Inc.), containing a gene for a red-
shifted GFP. A 3:1 molar ratio of the former to the latter was used, with a
total of 4 
 
m
 
g of DNA per well. Otherwise, cells were transfected as above.
At 36–48 h after transfection, cells were washed twice, fresh culture me-
dium was added, and the number of GFP-positive cells in a defined field
was determined by examination with a fluorescence microscope. Apopto-
sis was then induced by the addition of medium containing STS at the con-
centrations indicated, and the number of GFP-positive cells within the same
field was assessed at regular intervals over the next 24–42 h. To test the ef-
fect on bioactivity of adding GFP to the NH
 
2
 
 termini of the Bcl-2 family
members, a similar assay was performed on cells transfected with 2 
 
m
 
g of
the appropriate full-length or 
 
D
 
CT gene fused to GFP inserted into C3-
EGFP. For each construct, the assay was repeated three or four times. To
normalize for variations in transfection efficiency, changes in viability are
expressed as percentage decrease in the number of fluorescent cells within
a given field over time.
 
Results
 
GFP–Bax Is a Cytosolic Protein in Healthy Cells 
Whereas GFP–Bcl-2 and the Majority of Bcl-X
 
L
 
 
Associate with Mitochondria
 
We examined the location of Bcl-2, Bcl-X
 
L
 
, and Bax in in-
dividual living cells by using GFP fusion constructs. Fusion
constructs containing GFP have been successfully used to
study the subcellular localization of a number of proteins
(16, 26, 33). The gene encoding a high fluorescence, red-
shifted GFP variant (5) was fused to the 5
 
9
 
 termini of cDNAs
encoding human Bcl-2, Bcl-X
 
L
 
, or Bax. L929 murine fibro-
sarcoma and Cos-7 green monkey kidney epithelial cells were
transfected with the fusion constructs encoding GFP–Bcl-2,
GFP–Bcl-X
 
L
 
, and GFP–Bax.
The localization of these transiently expressed GFP–
linked fusion proteins was visualized in living cells using
confocal microscopy. In both Cos-7 (Fig. 1, 
 
a
 
 and 
 
b
 
) and
L929 cells (Fig. 2, 
 
a
 
 and 
 
b
 
), GFP alone has a diffuse distribu-
tion, filling the entire cell as previously reported (28).
GFP–Bcl-2 displays a punctate pattern of distribution, pri-
marily in areas near the nucleus, in both Cos-7 (Fig. 1, 
 
e
 
and 
 
f
 
) and L929 (Fig. 2, 
 
e
 
 and 
 
f
 
) cell lines. This distribution
matches the localization determined previously for Bcl-2
by immunofluorescence (24, 41), and suggests association
with an intracellular organelle or organelles. GFP–Bcl-X
 
L
 
displays a bright punctate distribution similar to that of GFP–
Bcl-2 superimposed upon a fainter diffuse background
(Figs. 1 and 2, 
 
i
 
 and 
 
j
 
), suggesting both soluble and mem-
brane-bound populations in individual cells. This is consis-
tent with the dual localization of Bcl-X
 
L
 
 in both the soluble
Figure 1. Distribution of
GFP-fusion proteins ex-
pressed in living Cos-7 cells,
before and after STS treat-
ment. At 48 h after transfec-
tion, cells were examined by
confocal microscopy. Each
field was visualized by laser
fluorescence to detect GFP
(a,  c,  e,  g,  i,  k,  m, and o), and
by DIC to illustrate cell mor-
phology (b, d, f, h, j, l, n, and
p). Native GFP (a and b) dis-
tributes throughout untreated
cells, that display a healthy
morphology. In contrast,
GFP–Bcl-2 (e and f) displays
a punctate distribution, mostly
perinuclear. GFP–Bcl-XL ( i
and j) appears to distribute in
a mainly punctate pattern
similar to GFP–Bcl-2, but also
has a faint diffuse fluores-
cence that extends through-
out cells. GFP-Bax (m and n)
distributes freely throughout
cells, in a pattern indistin-
guishable  from that of GFP
alone.  After 6 h of treat-
ment with 1 mM STS, Cos-7
cells assume a morphology
indicative of apoptosis, in-
cluding loss of cell volume,
retraction of processes, and
blebbing of cell membrane.
Despite these changes, native
GFP (c and d) still distributes throughout the cell. GFP–Bcl-2 (g and h) retains a punctate distribution after STS treatment. GFP–Bcl-XL
(k and l) also does not appear to change distribution with STS treatment, remaining mainly punctate with a background of diffuse fluo-
rescence. However, GFP–Bax (o and p) undergoes a striking change in distribution, becoming entirely punctate after STS treatment.
Bar, 20 mm.The Journal of Cell Biology, Volume 139, 1997 1284
and membrane pellets in cellular fractionation experiments
(14, 15). In contrast to the localization of GFP–Bcl-2 and
GFP–Bcl-XL, GFP–Bax has a diffuse distribution similar
to that of GFP alone in both Cos-7 (Fig. 1, m and n) and
L929 (Fig. 2, m and n) cell types.
We examined the GFP fusion protein expression by
Western blot analysis of transiently transfected Cos-7 cells
36 h after transfection. Immunoblotting of these lysates
confirmed that GFP–Bcl-2 (Fig. 3, middle, arrow a), GFP–
Bcl-XL (Fig. 3, bottom, arrow a), and GFP–Bax (Fig. 3,
top, arrow a) are of appropriate size. Low molecular
weight bands (lane c) representing native Bcl-2, Bcl-XL,
and Bax were detected in all lysates. An additional, unex-
pected protein band (arrow b) of intermediate molecular
weight was detected for each expression construct (Fig. 3).
This intermediate molecular weight form was also found
when COOH-terminal truncated forms of Bcl-2 (lane c),
Bcl-XL (lane e), and Bax (lane a) fused to GFP were ex-
pressed and immunoblotted. When compared to full-length
forms, all three COOH-terminal truncated proteins ran at
the expected slightly lower molecular weights (Fig. 3). The
COOH-terminal truncated constructs display slightly lower
molecular weights for both the high molecular weight and
intermediate molecular weight bands, indicating that the
intermediate weight bands likely represent proteins short-
ened from the NH2-terminal, GFP end, of the fusion pro-
tein. Thus, the intermediate size bands may result from ex-
pression of transcripts initiated at an internal start codon
within the GFP gene or proteolytic fragments lacking part
of the GFP molecule, and thus they may or may not fluo-
resce.
To determine if the fusion of GFP to Bcl-2, Bcl-XL, and
Bax affected their bioactivities, we compared the viability
of either L929 or Cos-7 cells transfected with wild-type
cDNA constructs to those transfected with GFP-fusion con-
structs after induction of apoptosis with STS. As shown in
Fig. 4, the protective activities of GFP–Bcl-2 (Fig. 4 A) and
GFP–Bcl-XL (Fig. 4 B) in L929 cells are comparable to those
of the wild-type forms. Likewise, the activity of GFP–Bax
appears to accelerate cell death of Cos-7 cells as effec-
tively as does wild-type Bax (Fig. 4 C). Thus, adding GFP
to the NH2-terminus of Bcl-2, Bcl-XL, or Bax does not
block their abilities to influence apoptosis. However, the
addition of a large protein to the NH2 terminus may alter
Figure 2. Distribution of
GFP-fusion proteins ex-
pressed in living L929 cells,
before and after STS treat-
ment. At 48 h after transfec-
tion, cells were examined by
confocal microscopy. Each
field was visualized by laser
fluorescence to detect GFP
(a,  c,  e,  g,  i,  k,  m, and o), and
by DIC to illustrate cell mor-
phology (b, d, f, h, j, l, n, and
p). Native GFP (a and b) dis-
tributes throughout healthy
cells. GFP–Bcl-2 (e and f)
displays a punctate perinu-
clear distribution. GFP–Bcl-XL
(i and j) appears to have both
punctate and diffuse frac-
tions. GFP–Bax (m and n)
distributes freely throughout
cells. After 6 h of treatment
with 1 mM STS, L929 cells
undergo a loss of cell volume
and retraction and blebbing
of extended processes. Na-
tive GFP (c and d) is found
throughout the cells after
STS treatment, including
blebs. GFP–Bcl-2 (g and h)
retains a punctate distribu-
tion after STS treatment. After
STS treatment, GFP–Bcl-XL
(k and l) shows a largely
punctate distribution with a
background of diffuse fluo-
rescence. As in Cos-7 cells,
GFP–Bax (o and p) under-
goes a change in distribution,
becoming punctate after
STS treament. Bar, 30 mm.Wolter et al. Bcl-2 Family Members Fused to Green Fluorescent Protein 1285
the potency of Bcl-2 family members to regulate apoptosis
or influence their intracellular localization.
To investigate the identity of the organelle or organelles
to which the GFP–Bcl-2 and the majority of the GFP–Bcl-XL
localize, we treated transiently transfected Cos-7 cells with
Mitotracker Red CMXRos. As shown in Fig. 5 (a–c), the
pattern of GFP–Bcl-2 distribution coincides very closely
with that of the mitochondrial marker, demonstrating that
most of the GFP–Bcl-2 is found associated with mitochon-
dria. The punctate fraction of the GFP–Bcl-XL also distri-
butes to mitochondria (Fig. 5, d–f). These results match
earlier findings localizing Bcl-2 and Bcl-XL to the mem-
brane of mitochondria using other imaging modalities (19,
24). In constrast to GFP–Bcl-2 and GFP–Bcl-XL, GFP–
Bax does not localize to mitochondria in healthy Cos-7
cells (Fig. 5, g–i).
FRAP Indicates Bcl-2 Is Largely Immobile Whereas 
Bax Diffuses Freely
The similarity of the distribution of GFP–Bax to the distri-
bution of GFP led us to investigate whether GFP–Bax is
free to diffuse within the cytoplasm, as GFP has been shown
to be (34). The mobilities of GFP–Bax and GFP were com-
pared by photobleaching the fluorescence in a small re-
gion of the cell and then monitoring the recovery of fluo-
rescence due to movement of unbleached molecules into
the bleached zone. Both GFP and GFP–Bax moved rap-
idly into the bleached zone (Fig. 6). The time courses for
Figure 3. Expression of truncated and full-length GFP–Bax, GFP–
Bcl-2, and GFP–Bcl-XL fusion proteins in COS cells. COOH-ter-
minal truncated and full-length GFP fusion constructs of Bax
(lanes a and b), Bcl-2 (lanes c and d) and Bcl-XL (lanes e and f)
were transfected into COS cells. The expression of the fusion
products was monitored by Western blotting of the cell lysates
with a human Bax 2D2, a human Bcl-2 8C8, and a universal Bcl-XL
2H12 monoclonal antibodies for the detection of Bax, Bcl-2, and
Bcl-XL, respectively. Arrows a are the expressed fusion products.
Arrows b are likely the in-frame NH2-terminal translational vari-
ants. Arrows c represent the endogenous simian Bax, Bcl-2, or
Bcl-XL that cross-react with the above specified antibodies.
Figure 4. Effect on cell viability of transient expression of wild-
type and COOH-terminal truncated forms of Bcl-2 family mem-
bers, with and without GFP fused at the NH2-terminus. Cells were
either singly transfected with the GFP fusion constructs or co-
transfected with GFP and various Bcl-2 family members. At 48 h
after transfection, cells were treated with STS. The number of
GFP-positive cells was counted within a given field at regular in-
tervals, starting at the time of STS addition (z500 GFP-positive
cells at time zero was typical for each experiment). Changes in
cell viability are displayed as number of glowing cells within a
field and expressed as a percentage of time zero value for that
field. (A) Bcl-2 constructs expressed in L929 cells. (n 5 4).
pcDNA3 vector control (e), Bcl-2 (s), GFP–Bcl-2 (d), Bcl-2
DCT (h), GFP–Bcl-2 DCT (j), and Bax (n) (B) Bcl-XL con-
structs expressed in L929 cells. (n 5 4). pcDNA3 vector control
(e), Bcl-XL (s), GFP–Bcl-XL (d), Bcl-XL DCT (h), GFP–Bcl-XL
DCT (j), and Bax (n) (n 5 4). (C) Bax constructs expressed in
Cos-7 cells. (n 5 3). pcDNA3 vector control (e), Bax (s), GFP–Bax
(d), Bax DCT (n), GFP–Bax DCT (m).The Journal of Cell Biology, Volume 139, 1997 1286
fluorescence recovery of GFP and GFP–Bax were essen-
tially identical (Fig. 6 B), and were consistent with diffu-
sion kinetics. The proteins diffused too rapidly relative to
the rates at which we could photobleach and monitor re-
covery to allow us to accurately determine diffusion con-
stants.
Photobleaching experiments also were performed on cells
expressing GFP–Bcl-2 (Fig. 6). In contrast to GFP and GFP-
Bax, GFP-Bcl-2 appeared to be largely immobile. The mobile
fraction (percentage recovery) at 100 s after photobleach-
ing (calculated as described in Materials and Methods) was
9 to 13% for GFP–Bcl-2 (n 5 3) as compared with 45 to
85% for GFP–Bax (n 5 4), and 82 6 2% for GFP alone
(34). The low mobility of GFP–Bcl-2 supports the conclu-
sion that it resides in discrete organelles (mitochondria)
rather than in a continuous membrane system such as the
endoplasmic reticulum (where fluorescence recovers rap-
idly after photobleaching [4]).
Role of Bcl-2 in Docking Bax
Recent studies have proposed that Bax (32) and Bad (40)
require Bcl-2 to associate with organelle membranes. To test
the possibility that GFP–Bax localization to organelles is
limited by the endogenous level of either Bcl-2 or Bcl-XL,
vectors expressing either Bcl-2 or Bcl-XL were cotrans-
fected with the GFP–Bax vector. As shown in Fig. 7 A, co-
expression of Bcl-2 at high levels, verified by immunoblot-
ting of cell lysates (Fig. 7 B), did not alter the cytoplasmic
distribution of GFP–Bax. Similar results were obtained
when Bcl-XL was coexpressed with GFP–Bax (data not
shown). Thus, we find Bax is a soluble, cytosolic protein in
healthy cells, which does not bind organelles even in the
presence of elevated levels of Bcl-2 or Bcl-XL.
Bax Localization and Mobility Change during Apoptosis
Endogenous Bax and some of the endogeneous Bcl-XL
migrate from the supernatant to the membrane pellets in
cell fractionation experiments performed on thymocytes
undergoing apoptosis (14). To investigate this phenome-
non in living cells, Cos-7 cells were transiently transfected
with native GFP, GFP–Bcl-2, GFP–Bcl-XL, and GFP–Bax.
Cells expressing each construct were treated with 1 mM
STS, and after 6 h both STS-treated and untreated cells
were examined by confocal microscopy. STS-treated cells
underwent cell shrinkage and blebbing of the cell mem-
brane, a morphology indicative of apoptosis (Fig. 1, com-
pare b, f, j, and n with d, h, l, and p). GFP–Bax markedly
changed its intracellular distribution, relocating within cells
during apoptosis from a diffuse (Fig. 1 m) to a punctate
pattern (Fig. 1 o). This change was not observed with GFP
alone (Fig. 1 c). No changes in the patterns of distribution
of either GFP–Bcl-2 (Fig. 1 g) or GFP–Bcl-XL (Fig. 1 k)
were observed in treated cells beyond those related to
changes in cell size and shape. It is possible that redistribu-
tion of soluble GFP–Bcl-XL is reduced to some extent in
this system due to the ability of overexpressed GFP–Bcl-XL
to inhibit apoptosis (Fig. 4 B). Similiar experiments per-
formed using another cell line, L929 fibroblasts, confirmed
that GFP–Bax undergoes a shift from a diffuse to punctate
distribution pattern during apoptosis whereas the localiza-
tion patterns of GFP–Bcl-2 and GFP–Bcl-XL remain es-
sentially unchanged (Fig. 2).
Mitochondrial staining of GFP–Bax–expressing Cos-7 cells
undergoing apoptosis suggests that much of the GFP–Bax
attaches to or enters mitochondria (Fig. 8, a–c). However,
as there are also sites of Bax condensation that do not
stain for mitochondria, it is possible that GFP–Bax is also
localizing to other organelles upon induction of apoptosis
or that mitochondria lose their Mitotracker Red CMXRos
staining during apoptosis.
The redistribution of Bax to organelles induced by STS
treatment is associated with a reduction in Bax mobility
(Fig. 6). FRAP experiments on cells in which GFP–Bax had
a punctate (mitochondrial) localization indicated that the
mobile fraction was 10 to 30% (n 5 2), as compared with
45 to 85% in untreated cells. Thus, the punctate form of
GFP–Bax is less mobile than the diffuse form of GFP–Bax
consistent with the model that Bax redistributes from a
cytoplasmic to membrane-bound localization during apop-
tosis.
Time Course of Bax Redistribution during Apoptosis
To relate the timing of the shift in GFP–Bax localization
to other morphological events that occur during apoptosis,
individual Cos-7 cells expressing GFP–Bax were followed
by confocal microscopy over the course of STS-induced
cell death. The change in GFP-Bax localization within in-
dividual cells occurred swiftly, over the course of z30 min
Figure 5. GFP–Bcl-2 and the punctate portion of GFP–Bcl-XL
colocalize with mitochondria in Cos-7 cells. Transiently trans-
fected Cos-7 cells were treated with 20 ng/ml Mitotracker Red
CMXRos to stain mitochondria and then examined by laser fluo-
rescence confocal microscopy. Each field was independently visu-
alized with the appropriate wavelength for GFP (a, d, and g) and
for Mitotracker Red CMXRos (b, e, and h) and then the two im-
ages were overlaid (c, f, and i). GFP–Bcl-2 localizes primarily to
mitochondria (a–c). A majority GFP–Bcl-XL also localizes to mi-
tochondria, although there is a faint, diffuse background which is
not punctate (d–f). GFP–Bax does not localize to mitochondria in
healthy cells (g–i). Bar, 20 mm.Wolter et al. Bcl-2 Family Members Fused to Green Fluorescent Protein 1287
after initiation (Fig. 9, c–e). Various cells in a given field
may begin the process of GFP–Bax redistribution at dif-
ferent times, as seen in Fig. 9. At the time point when
GFP–Bax begins redistribution, little alteration in the over-
all structure of the cell is evident when viewed by differen-
tial interference contrast (DIC) microscopy (Fig. 9 h), or
by interference reflection microscopy that shows the cell–
substrate interaction (data not shown). At 10–30 min after
the initiation of Bax redistribution, cell shrinkage first be-
came apparent by DIC imaging (Fig. 9, i and j, arrows).
Cells expressing GFP–Bax were incubated with the nu-
clear stain bis-benzamide (Hoechst 33342), which labels
DNA and is commonly used to detect the nuclear changes
characteristic of apoptosis. At low concentrations, this stain
can be used to study the location of DNA within living and
even dividing cells without affecting cell viability (8). After
bis-benzamide staining, cells were then treated with STS
to induce apoptosis. As shown in Fig. 10, there is no evi-
dence of nuclear changes when GFP-Bax initially begins
redistribution. At z3 h after the initiation of the GFP–Bax
transition, a more uneven pattern of bis-benzamide stain-
ing can be seen in the nuclei of cells (Fig. 10 e), suggestive
of nuclear condensation. This gradually progresses to nu-
clear fragmentation, clearly apparent by 12 h after initia-
tion of GFP–Bax redistribution (Fig. 10 f). Therefore, the
shift in GFP–Bax distribution appears to be an early event
in apoptosis, preceding several established morphological
changes associated with apoptosis.
COOH-terminal Hydrophobic Region Is Required for 
Bax Redistribution
The COOH-terminal hydrophobic region, spanning the last
20–24 amino acids of Bcl-2, Bcl-XL, and Bax is thought to
act as an anchor localizing these proteins to the membranes
of organelles. As our results suggest that Bax localizes to
organelles only upon induction of apoptosis, we investi-
gated the role of the COOH terminus in Bax trafficking.
DCT constructs of GFP–Bcl-2 (Fig. 11, a and c), GFP-Bcl-XL
(Fig. 11, e and g), and GFP–Bax (Fig. 11, i and k) all dis-
play a diffuse distribution in healthy cells, consistent with
localization throughout the cytosol, when expressed in ei-
Figure 6. FRAP analysis of GFP, and
GFP–Bax, and GFP–Bcl-2 in healthy and
cells treated with STS. (A) Fluorescence
recovery visualized in individual treated
cells. In a healthy Cos-7 cell expressing
GFP–Bax (a–d), fluorescence recovers
rapidly in a photobleached area. After
treatment with STS, a Cos-7 cell with
punctate GFP–Bax (e–h) no longer recov-
ers after photobleaching. In a healthy Cos-7
cell expressing GFP–Bcl-2 (i–l), recovery
does not occur in the photobleached area.
(B) Quantitative FRAP analysis to deter-
mine protein mobilities in cells expressing
GFP alone, GFP–Bax, and GFP–Bcl-2.
Fluorescence intensities during recovery
after photobleach are plotted versus time.
Data was collected at 0.46-s intervals dur-
ing recovery. GFP and GFP–Bax rapidly
recover with a time course consistent with
diffusion. GFP–Bcl-2 shows minimal re-
covery, indicating that it is largely immo-
bile. All intensity values were normalized
to prebleach intensity (I 5 100) and to the
intensity immediately after photobleach (I 5
0). Bars, 20 mm.The Journal of Cell Biology, Volume 139, 1997 1288
ther Cos-7 or L929 cell lines. Induction of apoptosis causes
no apparent redistribution of any of the DCT constructs in
either cell line (Fig. 11). This indicates that the COOH ter-
minus may play a pivotal role not only in anchoring Bcl-2
and Bcl-XL to organelles in healthy cells, but also in medi-
ating the organelle association of Bax observed in cells un-
dergoing apoptosis.
Deletion of the COOH-terminal Tail Attenuates the 
Influence of Bcl-2, Bcl-XL, and Bax on Cell Viability
If Bax insertion into organelles is required for death pro-
moting activity, then Bax DCT would be expected to have
diminished potential to enhance apoptosis relative to wild-
type Bax. The bioactivity of DCT constructs of Bax, Bcl-2,
and Bcl-XL was compared to that of the full-length genes
in a cell viability assay both with and without GFP fused to
the NH2 terminus of each protein upon induction of apop-
tosis with STS. As illustrated in Fig. 4, A and B, for both
Bcl-2 and Bcl-XL, deletion of the COOH-terminal hydro-
phobic domain resulted in a decrease in the apoptosis pro-
tection in L929 cells. For Bax, the deletion of the COOH-
terminal domain also resulted in a sharp decrease in the
ability of both wild-type and GFP-linked protein to accel-
erate apoptosis in both Cos-7 (Fig. 4 C) and L929 cells
(data not shown). These results indicate that the COOH-
terminal hydrophobic domain is important for Bax func-
tion, linking the ability of Bax to redistribute to organelles
during apoptosis with its death-accelerating activity.
Discussion
Bax promotes programmed cell death in mammalian cells
(18, 27). However, Bax expression per se, at least at physi-
ological levels, is not lethal to cells. For example, sympa-
Figure 7. GFP–Bax distribu-
tion in Cos-7 cells is not af-
fected by coexpression of
Bcl-2. Cells were transiently
transfected with a 3:1 ratio of
plasmid containing Bcl-2 and
GFP–Bax, and examined 48 h
later by confocal microscopy.
(A) In Cos-7 cells cotrans-
fected with Bcl-2 and GFP–
Bax, the GFP–Bax distributes
throughout the cell in a pat-
tern that is indistinguishable
from that of cells expressing
GFP–Bax alone. (B) The co-
expression of GFP–Bax and
human Bcl-2 in Cos-7 cells
was monitored by Western
blotting with a human Bax
2D2 and a human Bcl-2 8C8
monoclonal antibodies. Lanes
a are the Cos-7 cell lysates from transfection with the pcDNA 3 vector alone. Lanes b are the cell lysates from the pcDNA 3–Bcl-2 trans-
fection, and lanes c are from the cotransfection of C3–EGFP-Bax and pcDNA 3–Bcl-2. Arrows a, b, and c represent the GFP–Bax, its
NH2-terminal translational variant, and endogenous simian Bax, respectively. Bar, 20 mm.
Figure 8. GFP–Bax colocalizes with mito-
chondria in Cos-7 cells after STS treat-
ment. Cos-7 cells transiently expressing
GFP–Bax  were treated with 1 mM STS to
induce apoptosis and with 20 ng/ml Mi-
totracker Red CMXRos to stain for mito-
chondria and then examined after 4 h by
laser fluorescence confocal microscopy.
The field shown was independently visual-
ized by laser fluorescence confocal micros-
copy at the appropriate wavelength for
GFP (a) and for Mitotracker Red
CMXRos (b), and the two images were
then overlaid (c). Whereas a majority of
the punctate GFP–Bax appears to localize
to mitochondria, there are also areas
where the GFP–Bax is punctate but which
do not label with the mitochondrial dye (c,
arrow). Bar, 20 mm.Wolter et al. Bcl-2 Family Members Fused to Green Fluorescent Protein 1289
thetic neurons express high levels of bax mRNA, yet will
not undergo apoptosis unless deprived of growth factors
(6). As initially characterized, even cells stably overex-
pressing Bax proliferate normally (27), and Bax only ac-
celerates cell death after an external signal, such as inter-
leukin-3 withdrawal. As protein levels of Bax do not
change during apoptosis (14, 27), it seems plausible that a
posttranslational activation of Bax occurs during apopto-
sis. Our findings indicate that Bax activity may be regu-
lated at the level of intracellular localization, with Bax
moving to the membranes of organelles after induction of
apoptosis, but before nuclear fragmentation. Elimination
of 21 amino acids from the COOH terminus prevents Bax
redistribution and abrogates Bax apoptosis-promoting ac-
tivity, correlating organelle binding with bioactivity.
In contrast to cytosolic GFP–Bax, GFP–Bcl-2 displays a
punctate distribution in healthy cells that coincides very
strongly with a mitochondrial marker. GFP–Bcl-XL dem-
onstrates a mixed pattern, suggesting that although much
of the protein is associated with mitochondria, a significant
amount is found diffusely throughout the cytosol. In cell
fractionation studies, this soluble Bcl-XL found in healthy
cells redistributes to associate with the membrane during
apoptosis (14). No change in distribution is observed for
either GFP–Bcl-2 or GFP–Bcl-XL after the addition of STS.
However, the levels of GFP–Bcl-XL in the transfection ex-
periments are sufficient to delay or even block apoptosis
(Fig. 4); thus, GFP–Bcl-XL may actually prevent alter-
ations in the intracellular milieu that would lead to its re-
distribution. Further experiments will be necessary to ex-
plore the intracellular distribution of GFP–Bcl-XL during
apoptosis, perhaps by using apoptosis pathways that are
Bcl-XL insensitive.
For all three of the Bcl-2 family members examined here,
the COOH-terminal deletion eliminates the ability of GFP-
tagged proteins to associate with organelles. The depen-
dency of Bax redistribution on the COOH-terminal hy-
drophobic domain suggests that a conformational change
or other modification might occur in Bax during apoptosis,
allowing the previously inaccessible or blocked hydropho-
bic tail to insert into membranes. It is striking that the
translocation domain of diphtheria toxin, which has struc-
tural homology to Bcl-XL, displays a similar ability to
change from a soluble to membrane-associated state. In
the case of the diphtheria toxin translocation domain, this
insertion is driven by a conformational change triggered
by low pH (7, 30). It remains unclear how Bax insertion
into membranes is controlled. One interesting candidate is
phosphorylation: a regulatory mechanism involving phos-
phorylation has recently been described that influences
both localization and activity of the apoptosis promoter
Bad (40), and phosphorylation of Bcl-2 has been suggested
to regulate its function (10, 17, 22).
Our findings conflict with previous reports that suggest
that Bax is constitutively localized to organelle membranes
(for review see reference 29). One possible explanation for
this discrepancy may be that in earlier work, Bax localiza-
tion was examined in contexts where overexpression of
Bax alone was sufficient to cause apoptosis, without the
overt induction of apoptosis. In a study examining Bax lo-
Figure 9. GFP–Bax redistribution occurs
before cell shrinkage associated with apop-
tosis. A field containing three living Cos-7
cells expressing GFP–Bax was followed
over time after addition of 1 mM STS. At
each timepoint, the field was visualized by
laser fluorescence to detect GFP–Bax (a–e
and  k–o), and by DIC to illustrate cell
morphology (f–j and p–t). Time elapsed
after addition of STS is indicated in the
corner of each of the laser fluorescence
panels. Redistribution of the GFP–Bax
was first detectable for the two cells to-
wards the top of the field at 1 h, 24 min af-
ter STS addition (c). Changes in cell shape
first became apparent 12–24 min later, as
evidenced by a retraction of cell outlines
(arrows, i and j). Notice that at these time-
points, the lowermost cell has not yet initi-
ated either GFP–Bax redistribution or cell
shrinkage. GFP–Bax redistribution is first
detectable for the lowermost cell at 2 h,
36 min (n). Bar, 20 mm.The Journal of Cell Biology, Volume 139, 1997 1290
calization in a transformed BRK cell line, Bax overexpres-
sion led directly to cell death (11). A recent paper on Bax
localization to mitochondria (39) reported that the expres-
sion of fusion proteins containing full-length Bax was lethal
to yeast cells, and removal of the COOH terminus abol-
ished the ability of Bax to kill yeast cells and localize to yeast
mitochondria. We have found that cationic lipid transfec-
tion procedures can themselves trigger apoptosis (Wolter,
K.G., and X.-G. Xi, unpublished observations). Deletion
of the COOH-terminal tail from GFP-Bax eliminated this
increase in transfection-associated death. High levels of
full-length GFP–Bax expression may, therefore, lead di-
rectly to the death of transfected cells, particularly if this
expression closely follows the cellular stress of the trans-
Figure 10. GFP–Bax redistribution pre-
cedes nuclear fragmentation. A field con-
taining three living Cos-7 cells expressing
GFP–Bax was followed over time after ad-
dition of 1 mM STS, and 100 ng/ml of the
nuclear stain bis-benzamide (a–e). In each
panel, laser fluorescence confocal micros-
copy was used at the appropriate wave-
length to visualize GFP (green) and bis-
benzamide (blue). Time elapsed after STS
addition is indicated in each panel. After
15 h (f) cells show fragmented nuclei asso-
ciated with apoptosis. Bar, 20 mm.
Figure 11. Distribution of
GFP-fusion proteins lacking
COOH-terminal hydropho-
bic domains before and after
STS treatment. Cos-7 and
L929 cells were transiently
transfected with the appro-
priate construct, and exam-
ined 48 h later by confocal
microscopy. Each field was
visualized by laser fluores-
cence to detect GFP. In both
healthy Cos-7 cells (a) and
L929 cells (c), DCT GFP–
Bcl-2 was diffusely distrib-
uted throughout the cytosol.
Likewise, in healthy Cos-7
cells (e) and L929 cells (g),
DCT GFP–Bcl-XL was dif-
fusely distributed throughout
the cytosol. Finally, in both
healthy Cos-7 cells (i) and
L929 cells (k), DCT GFP–
Bax was diffusely distributed
throughout the cytosol. Cells
expressing truncated GFP-
fusion proteins were treated
with 1 mM STS, and exam-
ined after 6 h. In both Cos-7
cells (b, f, and j) and L929
cells (d, h, and l), none of the
truncated proteins redistrib-
uted after STS treatment.
Bar, 20 mm.Wolter et al. Bcl-2 Family Members Fused to Green Fluorescent Protein 1291
fection procedure. Perhaps some previous observations of
organelle-located Bax were made on cells entering an apop-
tosis program. These reports and our own data concur in
suggesting that Bax localization to organelles is a vital as-
pect of its death promoting ability.
However, our findings on the role of Bcl-2 in Bax local-
ization clearly differ from those of Shibasaki and co-work-
ers (32), who observed a redistribution of soluble Bax to a
punctate pattern in BHK cells expressing high levels of
Bcl-2. In our systems, we see no evidence for a localization
of Bax to membranes driven by either Bcl-2 or Bcl-XL co-
expression. This is consistent with earlier findings that Bax
and Bcl-XL do not form heterodimers in healthy cells (15).
Recent reports indicate that Bcl-2 family members con-
trol the release of cytochrome C and apoptosis-inducing
factor from mitochondria during apoptosis and contribute
to cell death by caspase activation (20, 21). The overex-
pression of Bcl-2 has been reported to block the mitochon-
drial release of cytochrome C, and in doing so prevents
apoptosis (38). These results are interesting, given the struc-
tural connection made between Bcl-XL and the diphtheria
toxin translocation domain. This domain is capable of form-
ing transmembrane ion channels, and is furthermore be-
lieved to multimerize to form pores that mediate the trans-
location of the catalytic domain of the diphtheria toxin across
membranes. Bcl-XL and Bcl-2 have been reported to form
transmembrane channels (23, 31). In this context, it is pos-
sible that upon Bax insertion into membranes, Bax may
form channels or pores allowing for the release of factors
such as cytochrome C from within the mitochondria to
propagate the apoptotic pathway. This model does not pre-
clude the interaction of Bax with Bcl-2 and Bcl-XL upon
membrane insertion. In the future, it will be crucial to elu-
cidate the trigger regulating Bax insertion into organelle
membranes and the molecular consequences of mem-
brane-bound Bax.
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